



## Missouri Pharmacy Program – Preferred Drug List



### Fibromyalgia Agents

**Effective 06/02/2010**

Revised 01/05/2012

#### Preferred Agents

#### Clinical Edits May Apply

- Savella®
- Cymbalta®

#### Non-Preferred Agents

#### Clinical Edits May Apply

- Lyrica®

<u>Approval Criteria</u>	<u>Denial Criteria</u>										
<ul style="list-style-type: none"> <li>• Appropriate Diagnosis for each agent:               <ul style="list-style-type: none"> <li>• Cymbalta® and Savella®                   <ul style="list-style-type: none"> <li>i. Therapy will be approved for the following indications:</li> </ul> </li> </ul> </li> </ul> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <thead> <tr> <th style="width: 50%; text-align: center;">Condition</th> <th style="width: 50%; text-align: center;">Submitted ICD-9 Diagnoses</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">Fibromyalgia</td> <td style="text-align: center;">729.1</td> </tr> </tbody> </table>	Condition	Submitted ICD-9 Diagnoses	Fibromyalgia	729.1	<ul style="list-style-type: none"> <li>• Failure to meet approval criteria</li> </ul>						
Condition	Submitted ICD-9 Diagnoses										
Fibromyalgia	729.1										
Failure to achieve desired therapeutic outcomes with trial on <b>1 preferred agents</b>	<ul style="list-style-type: none"> <li>• Concurrent use of Monoamine Oxidase Inhibitors</li> </ul>										
Documented trial period for preferred agents	Children of 17 years of age and younger (Subject to Clinical Consultant Review)										
Documented ADE/ADR to preferred agents	Lack of adequate trial on preferred agents										
Documented compliance on current therapy regimen	Drug Prior Authorization Hotline: (800) 392-8030										
<ul style="list-style-type: none"> <li>• Lyrica®               <ul style="list-style-type: none"> <li>i. Therapy subject to following indications diagnostic criteria</li> </ul> </li> </ul> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <thead> <tr> <th style="width: 50%; text-align: center;">Condition</th> <th style="width: 50%; text-align: center;">Submitted ICD-9 Diagnoses</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">Peripheral Neuropathy assoc. with diabetes</td> <td style="text-align: center;">250.6 356.9 357.2</td> </tr> <tr> <td style="text-align: center;">Postherpetic Neuralgia</td> <td style="text-align: center;">053.12 053.13 357.0</td> </tr> <tr> <td style="text-align: center;">Partial Epilepsy</td> <td style="text-align: center;">345.4 345.5</td> </tr> <tr> <td style="text-align: center;">Fibromyalgia</td> <td style="text-align: center;">729.1</td> </tr> </tbody> </table>	Condition	Submitted ICD-9 Diagnoses	Peripheral Neuropathy assoc. with diabetes	250.6 356.9 357.2	Postherpetic Neuralgia	053.12 053.13 357.0	Partial Epilepsy	345.4 345.5	Fibromyalgia	729.1	<ul style="list-style-type: none"> <li>• After 90 days of Fibromyalgia Agent therapy, documentation of more than three medications from the five drug classes listed below:               <ul style="list-style-type: none"> <li>○ In any combination as a treatment for fibromyalgia</li> </ul> </li> </ul> <p style="margin-top: 10px;">Most Common Drug Classes Concurrently used in Fibromyalgia Treatment</p> <ul style="list-style-type: none"> <li>• Tricyclic Antidepressants (TCA)</li> <li>• Selective serotonin reuptake inhibitors (SSRI)</li> <li>• Long-Acting Opioid</li> <li>• Short-Acting Opioid</li> <li>• Skeletal Muscle Relaxants</li> </ul>
Condition	Submitted ICD-9 Diagnoses										
Peripheral Neuropathy assoc. with diabetes	250.6 356.9 357.2										
Postherpetic Neuralgia	053.12 053.13 357.0										
Partial Epilepsy	345.4 345.5										
Fibromyalgia	729.1										